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The era of imaging neuroreceptors in humans with PET was ushered in by Wagner et al.
(1983) with a report in Science showing the first human brain scan of dopamine receptors
(Wagner, 1983). The tracer was N-methylspiperone (NMSP) tagged with carbon-11. The brain
that was scanned belonged to one of the authors. Ethical concerns notwithstanding, this act
placed the researchers in the good company of famous scientists throughout history who had
experimented on themselves. The publication of this paper excited the field and garnered some
publicity as well (see Figure 1). Although the study did not employ the quantitative analysis
techniques we describe below, it presaged some of the key concepts. Namely: (1) early images
contain mostly blood flow information; (2) late images primarily reflect binding; (3) radioactive
tracer in the target tissue can be “free” or “bound”, which often necessitates the examination
of a “reference region”, which is devoid of receptor sites; (4) co-injection of radiolabelled tracer
with an excess of unlabeled tracer can be used to prevent radiotracer from binding and thus
measure unbound (aka, non-displaceable) signal by itself. Injection of excess unlabeled tracer
is generally not performed in humans; in this case, it was done in baboons. As we discuss
below, the ability to use PET to measure receptor number or some index thereof opens up
additional measurement possibilities which take advantage of a key concept: competition. In
the Wagner paper, the competition was between hot (labeled) and cold (unlabeled) tracer
(Wagner, 1983). In another ground-breaking paper that followed it, the competition was
between a radiotracer and an unlabeled neuroleptic drug (Farde et al., 1986). Farde and
colleagues did what amounts to the first drug occupancy study with PET using the tracer,
[11C]raclopride, in 1986. Their paper was intended to examine the occupancy level of drugs for
schizophrenia in treated schizophrenics by examining the degree of tracer blocking at the
dopamine D2 receptor sites achieved by each patient’s respective drug. Whereas Wagner et
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al. could examine the difference between a baboon at baseline and following a co-injection of
tracer with an excess of cold NMSP (Wagner, 1983), Farde et al. did not ask their patients to
go off medication to get a baseline measurement of tracer binding (Farde et al., 1986). So how
did they make an assessment of drug occupancy, which requires at least two measurements?
They extrapolated what baseline binding might have been in their schizophrenics from a cohort
of control subjects. Provocatively, they found that three schizophrenics undergoing (success‐
ful) treatment with different drugs all had receptor occupancies of very similar levels. Their
approach would likely not pass muster today, but at the time, the paper was highly innovative,
and it foreshadowed one of the major usages of PET and neuroreceptor tracers: measuring
target occupancy by drugs in people.
Figure 1. Left) Newspaper clipping from the Baltimore Sun, Sept 20, 1983, shows senior authors, Drs. Henry Wagner,
Jr. and Mike Kuhar observing the first images of D2 receptors in a human brain, in vivo. (Right) A keepsake from the
experiment adorns the offices of many of the landmark study’s participants. Signatures, from the center bottom going
clockwise, Wagner, Robert Dannals, Joanthan Links, Dean F. Wong, Jim Frost, and Kuhar. Photos care of M. Kuhar.
1.2. Basics
1.2.1. Molecular specificity
PET is unique among medical imaging modalities for its exquisite molecular specificity. From
this specificity, PET derives its unique ability to image highly selective biological processes –
that is, to act as a functional imaging modality. In the brain (and everywhere in the body),
different processes are facilitated by highly specialized molecules. Individual enzyme mole‐
cules exist to catalyze highly selective and uni-purpose biochemical reactions. Unique
receptors and transporters exist to bind highly specialized endogenous ligands and carry out
unique physiological functions. Some of the functions of interest that are controlled by
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individual molecules and which we may want to image are shown in Figure 2. PET can image
any of these molecular targets provided two obstacles have been overcome. First, a tracer
molecule that binds or interacts with the target site must exist and be labeled with a positron
emitting isotope (typically, carbon-11 or fluorine-18). Second, it must be possible to deliver the
tracer to the target site. In brain imaging, the most likely cause of tracer failure is the inability
of the tracer to cross the blood brain barrier to access the target.
Figure 2. Molecular processes that can be imaged with the appropriate PET ligand. Figure modified (Pellerin et al.,
1994).
1.2.2. Many tracers for many targets
At this writing, there are tracers for many of the common neurotransmitter receptor sites:
dopamine (D2/D3 and D1), serotonin (5HT1a, 5HT1b, 5HT4…), and transporter sites (DAT, SERT,
NET…). Tracers generally arise through one of three pathways. (1) Radiolabeling of a dye or
other molecule that is known to be selective for a particular target of interest (e.g., [11C]PIB
arose from the radiolabelling of thioflavin-T) (Mathis et al., 2002). (2) Radiolabeling of a
candidate drug for the target molecule of interest. Such candidate compounds may have been
failed drugs (adverse drug side-effects on patients, kinetics too rapid to sustain clinically useful
levels in blood and tissue) but make good tracers (no adverse side-effects, because tracers are
given in micro-dose amounts, favorably rapid kinetics). (3) De novo design of new PET tracer
based on knowledge of the structure of the target molecule.
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1.2.3. Specific binding vs. nonspecific background
Tracers are administered to subjects intravenously and travel to the brain via the circulation.
Once they traverse the blood brain barrier (typically by passive diffusion), they can follow
three possible fates. Some tracer molecules remain free (unbound), eventually clear back to the
vasculature and are removed from the organ. Other tracer molecules, once inside the tissue,
may bind to the specific target of interest. Because no tracers are perfectly ideal in their
behavior, some molecules are bound nonspecifically (nondisplaceably) before clearing from
the tissue. Thus, in toto, radioactive emissions that are detected by the PET scanner are a (time-
varying) sum of emissions of radio-isotopes on tracer molecules in all four different possible
states: blood-borne, free in tissue, specifically bound to a receptor or other target molecule, or
nonspecifically bound (Figure 3). The PET scanner records all of these emissions indiscrimin‐
ately. Nothing about the photons that are emitted from an annihilation event in the blood or
tissue makes their original state knowable from the detected signal. Thus, on any given static
PET image (a single image summed over a time frame), the desired signal – i.e., the amount
of specifically bound tracer – cannot be discerned easily because the signal is confounded by
background activity coming from tracer in its three other possible states.
Figure 3. Possible states of an injected radiotracer. The states can be thought of as distinct, interconnected pools. Fig‐
ure modified (Pellerin et al., 1994).
The one thing that allows us to differentiate the binding from the background is the difference
in temporal behavior of the various tracer states. The persistence of activity (in a sense, the
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residence time) in each of the plasma, free, bound, and nonspecific pools is different (see curves
in Figure 4). Thus, to identify the specific binding component of the total PET signal (green
curve on Fig. 4, also called a time-activity curve (TAC)), we must (a) acquire dynamic data
(over many time frames), (b) identify an input function to the system (either plasma radioac‐
tivity or image-derived), and (c) apply a mathematical model to separate the dynamic data
into its constituent parts.
Figure 4. Different pools (compartments) of tracer activity are distinguishable by their different kinetics. Plasma activi‐
ty (red) is cleared fastest. The free tracer pool (white) is slightly slower. The bound tracer pool (yellow) persists for lon‐
gest. The PET scanner measures the sum of all the radiactivity (green).
1.2.4. Binding potential as endpoint
The most common endpoint for imaging neuroreceptor or neurotransmitter targets with PET
is the compound parameter, binding potential (BP). The term was first introduced by Mintun
and is equivalent to the steady state ratio in the target tissue of specifically bound tracer to free
tracer (Mintun et al., 1984). Binding potential is a “compound” parameter, because it is
equivalent to the ratio of individual rate constants (specifically, the association and dissociation
rate constants). The rate constants arise in the standard compartmental model used to describe
a TAC measured in a region of interest in the dynamic PET images. Readers should be aware
that there are a few variations on the definition of binding potential (Innis et al., 2007). The
definitions differ by what data are used as the input function to drive the particular kinetic
model and by what assumptions are made. Nevertheless, the general principle can be stated:
BP can be estimated as the steady state ratio of bound to free tracer. BP is also proportional to
the available binding sites and inversely proportional to the equilibrium dissociation constant,
KD, of the tracer for the binding site. The former concept is diagrammed in Figure 5. We see
that there are four species of interest in imaging neuroreceptor targets. First, the receptor,
second, the tracer molecule that binds to the target and emits a positron, third, the unlabeled
tracer which also binds to the target but emits no positron, and fourth, the endogenous ligand
that is also specific for the target but (naturally) emits no positron.
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Figure 5. Binding potential depicted as bound over free tracer (red with star) at steady state. Receptor (or transporter)
molecules (blue) may be embedded in a cell membrane. Two other species compete with tracer for limited binding
sites: cold tracer (red), endogenous ligand (green).
1.2.5. Changes in receptor number
As previously stated, BP is proportional to number of available receptor binding sites and
typically serves as a convenient surrogate for receptor density, provided the proportionality
constant can be taken as a constant across the groups or conditions being compared. When BP
is estimated from dynamic data using the arterial plasma concentration of tracer as the input
function, the proportionality between BP and Bmax is simply 1/KD. (i.e., BP = Bmax/KD). Perhaps
the most common use of BP as an endpoint is to assay receptor density (e.g., dopamine D2R)
in two groups of subjects (e.g., healthy controls and cocaine addicts) and compare them
(Martinez et al., 2003; Volkow et al., 1997). In such a case, the density of receptors may be
believed to have a direct functional role in a disease process. Alternatively, receptor number
can be a surrogate marker for number of functioning neurons. Consider Parkinson’s disease
(PD), which involves loss of nigro-striatal connections. Because functioning nigro-striatal
projections contain D2 receptors and dopamine transporters on their striatal terminals, absence
of such sites in a PET scan is indicative of disease progression and attendant loss of neurons.
Low dopamine receptors and low dopamine transporters have each been demonstrated with
either [11C]raclopride or [11C]CFT, respectively, by comparing the BP for healthy controls to
that of PD patients (Biju et al., 2009; Brooks et al., 1990). The schematic in Figure 6 represents
the case of low BP caused by low receptors (Figure 6 should not be interpreted too literally.
e.g., in the case of PD, the entire cell membrane along with the receptors might be missing).
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1.2.6. Changes in endogenous neurotransmitter
Another popular use of BP is as a measure of steady state neurotransmitter level. Such
measurements are typically made by comparing BP in the same subject at baseline and in a
drug or treatment condition. This can be done via two paired bolus injections of tracer or via
one bolus plus infusion of tracer (see section 1.2.10 below). Typically, a drug will be given prior
to the PET scan. The drug (e.g., cocaine, methylphenidate, amphetamine) will cause elevation
of endogenous neurotransmitter, which will in turn occupy more binding sites. As a result,
fewer binding sites will remain available for binding by the labeled tracer, and the measured
BP will be lower than at baseline. The fractional change in BP is the parameter that is most
often reported as an indicator that there has been a prolonged change in neurotransmitter level
(Here, “prolonged” simply means on the order of, or longer than, the scan duration). Figure
7 illustrates the principle using the same scheme as in Figures 5 and 6. Because specific binding
sites exist in limited number, the approach to full binding will follow a saturation curve. That
is, for greater and greater amounts of neurotransmitter release, we expect to see less and less
incremental reduction of binding potential.
Figure 6. Lower Binding Potential reflects lower receptor density. (Compare to Figure 5).
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Figure 7. Elevation of endogenous neurotransmitter (green triangles) blocks available receptors and is detected as a
reduction in BP.
1.2.7. Changes in occupancy by an exogenous drug
A third common usage of PET and BP is for measuring occupancy of receptor sites by
exogenous (unlabeled) drugs. This is a popular use of PET by pharmaceutical companies who
typical want to know three things: (a) does their candidate drug get into the brain, (b) does the
candidate drug hit the intended target, and (c) what is the relationship between dose of the
drug and percentage occupancy of the available (target) receptors? When companies are ready
for a drug-occupancy study with PET they usually already know the safe dose range of the
drug (i.e., the range of doses that cause little to no adverse side-effects). They also have a desired
occupancy level in mind that will produce the desired drug effects. The question that PET can
answer is: what is the receptor occupancy for each dose level in the allowable range. This
relationship is characterized by an ED50 (drug dose at which 50% occupancy is achieved) and
an Emax (maximal achievable level of binding if there were no upper limit on dose). Just as with
elevation of endogenous neurotransmitter, the presence of cold exogenous drug that binds to
the same receptor as the tracer and reduces the concentration of available receptor sites can be
imaged. This scenario is diagrammed in Figure 8. An essential element of occupancy studies
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is that there must exist a tracer that binds selectively to the desired drug target. On the other
hand, the drug need not be selective. The change in binding of the PET tracer will reflect the
occupancy of the drug only at the tracer’s target. Again, occupancy of specific receptor binding
sites is saturable and reduction in BP (i.e., increase in drug occupancy) increases less and less
for given increases in drug as the concentration gets higher and higher. We typically define
change in BP as a percentage change:
ΔBP = [1 - BP(under a challenge condition) / BP(at baseline) ]* 100.
For the case of an exogenous drug binding to target sites, it turns out, Occupancy = ΔBP.
Figure 8. Effect of exogenous drug on binding potential. Drug (yellow triangles) occupies some receptor sites reduc‐
ing available binding sites and then reducing BP.
1.2.8. Ambiguities in interpretation of PET data
The flexibility of BP as an endpoint of PET studies with neuroreceptor ligands (as stated, one
can measure receptors, transmitters, drugs) is also the source of potential ambiguity in
interpretation. How can one tell the difference between lower receptor density under scan
condition B vs. A from higher neurotransmitter level in scan condition B vs. A? These ambi‐
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guities are inherent in the compound parameter, BP. Generally, they can be resolved by
considering the context of the measurement. If a stimulus was given just before the scan and
the BP was lower than at baseline, we interpret this to mean that neurotransmitter levels rose
due to the stimulus. We reject receptor up-regulation as the explanation, because it is a slower
process than the time-scale of the PET scan (1-2 hours). On the other hand, if baseline scans
are repeated on the same individuals after a year of psychotherapy and the average BP value
is higher in the latter scan, we interpret this to mean that receptor number is increased by
psychotherapy. (We must admit that long-term depression of baseline neurotransmitter level
is also a valid interpretation.) Certainly we can say that “available receptor sites” were
increased with therapy. In all cases, one must be alert to alternative interpretations of BP and
∆BP and try as best as possible to control for them via appropriate study designs.
1.2.9. Common confounding conditions in PET experiments
Some sources of ambiguity in the interpretation of BP measurements are inherent in the nature
of PET data, but others can and should be controlled experimentally.
1.2.9.1. Effect of age
The densities of many neuroreceptors are known to decline with normal aging and this has
been confirmed with PET (E. D. Morris et al., 1999). Thus, BP will be lower in a group of healthy
control subjects with a higher mean age than a second group whose mean age is younger.
Similarly, there may be no effect of a treatment or condition (e.g., long-term drug abuse) on
the numbers of a particular receptor, but it might appear so if the drug abusers have a mean
age that is older than the mean age of the healthy subjects to whom they are being compared.
Any careful reading of journal articles reporting BP values for different cohorts must include
checking to make sure that the ages of the respective groups are not different. Similarly, a
longitudinal study examining the effect of long-term treatment on a single group of individuals
should correct for aging of the subjects if the length of the study is considerable.
1.2.9.2. Effect of mass
As we saw above, an exogenous drug that occupies the target receptor reduces available
binding sites for the tracer, and BP is reduced. This is the basis for drug occupancy studies.
However, if the specific activity of the tracer (ratio of activity to mass) is low enough, then
mass of cold tracer acts like any exogenous drug. This poses two problems. First, we normally
do not want the tracer species to exert its own drug effects. Second, the mass of cold tracer –
as with any exogenous ligand for the target site – will occupy an appreciable number of
receptors and the measured BP will be lower than if the mass of tracer were negligible.
Unwanted drug effects notwithstanding, poorly controlled mass of tracer has the potential to
introduce a confound into an experiment. If a patient group is being compared to a control
group but the patients receive a significantly higher mean tracer mass (i.e., lower specific
activity for the same amount of radioactivity injected), then the patients will appear to have
lower BP due to their disease, when in fact, the difference may be caused solely by a bias
introduced by experimenters.
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1.2.10. Experimental approaches to estimate binding potential
There are generally two approaches to estimating BP and by extension, change in BP. Both
approaches turn on recognizing that BP represents a steady state quantity: the ratio of bound
to free tracer in the tissue at steady state – that is, when the ratio of these quantities is not
changing on a macroscopic level. To make such a measurement, one can either perform an
experiment that brings the pools of bound and free tracer to steady state or, if that is not possible
or not desired, one can predict the steady state from non-steady measurements. If these ideas
seem unintuitive, consider the two fun experiments depicted in Figure 9 for predicting the
steady state (i.e., adult) height of one’s daughters. Steady state approach: one can make a few
measurements (greater reliability than a single measurement) once the child reaches her adult
height (Figure 9, left). Non-steady approach: one can make periodic measurements throughout
childhood and – given a model of growth patterns of women in the United States – predict the
adult height of the child based on these non-steady measurements (right).
Figure 9. Schematic for (left) a type of steady state experiment for measuring height of a fully grown female child, as
compared to (right) a type of non-steady experiment for predicting the adult height of the female children of one of
the authors.
1.2.10.1. Bolus plus constant infusion
In PET, the steady state or equilibrium approach to measuring BP consists of administering
the tracer as an initial bolus followed by a constant infusion of additional tracer for the duration
of the experiment. If the bolus and infusion fractions of the tracer are balanced correctly, the
TAC in the region(s) of interest will achieve a steady state in a minimal amount of time (Carson
et al., 1993) at which point tracer concentrations in plasma, free and bound compartments will
remain in constant proportions to each other. At said point, BP can be measured directly from
the levels of the plasma and tissue curves without the need for a model or any curve-fitting.
It must be pointed out that infusions are more taxing experimentally. An infusion pump is
required. More tracer is required (as compared to a bolus injection), since some of it decays
while sitting in the syringe waiting to be infused. Not all tissue regions are the same. Tissue
regions with differing kinetics of tracer uptake will reach equilibrium at different times – or
not at all. Not all subjects are the same. For a given injection protocol, one subject’s tissue curves
might reach equilibrium but another’s might not.




Alternatively, if an infusion experiment is impractical, a bolus administration of tracer is used.
This approach includes a bolus injection of tracer, a dynamic acquisition of PET data, and a
kinetic model to fit the data, estimate parameters, and calculate BP from the estimated model
parameters. The parameters of the kinetic model are rate constants (they each have units of
time-1), but their ratio is an equilibrium (i.e., steady state) constant (BP is unitless).
Both experimental designs (bolus and bolus/infusion) can be used to measure the change in
BP. In the case of the bolus administration, two separate injections are required to measure
change in BP (ΔBP) – perhaps in response to a drug challenge. A single bolus plus infusion (B/
I) study can suffice to measure ΔBP provided the drug challenge of interest acts rapidly enough
and the tracer is sufficiently displaceable so that the effect can be detected during the duration
of the scan. The two different paradigms for measuring ΔBP are diagrammed in Figure 10.
Each paradigm has advantages and disadvantages that the investigator must consider
carefully when planning a study (Table 1). The order of a paired bolus study (baseline vs.
challenge condition) can be randomized; the B/I cannot. Both scans of a paired bolus studies
with 18F-labelled tracers cannot both be performed on a single day. This may lead to greater
variability in the data or even loss of some subjects who fail to return for a second scan.
Equilibrium must be reached before the drug challenge in the B/I design. Unfortunately, there
is no way of knowing that equilibrium has been achieved in a subject before giving the drug
challenge, since PET data are not reconstructed and analyzed in real time. Finally, on the side
of the B/I paradigm, the analysis of the data – provided equilibrium has been reached – is
simple and requires no modeling and no curve fitting. For bolus studies, with some rare
exceptions, one must use a kinetic model to describe the data in order to estimate BP.
Figure 10. Two common schemes for measuring change in BP with PET. General appearance of data from a paired
bolus study (left) compared to a single bolus plus infusion study (right). Stars on right indicate that only two static
measurements are necessary to get change in BP from an equilibrium study
1.2.11. Modeling basics (to get to binding potential via bolus or bolus + infusion)
As we discussed in Section 1.2.3 and diagrammed in Figure 4, the PET signal consists of tracer
molecules in different pools, only one of which is the specific binding we are most interested
in. These pools or compartments differentiate themselves over time. They have different
temporal characteristics based on their degree of retention of the tracer. The PET signal can be
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dissected into its constituent parts with the use of a kinetic model that describes the processes
of uptake and retention of the tracer, as well as the interconnectedness of the compartments.
1.2.11.1. The modeling process
The process of moving from some knowledge of the system of interest to a tracer kinetic model
is diagrammed in Figure 11. One must first identify the organ(s) of interest. In the case of
imaging drugs, the organ, naturally, is the brain. Next one must consider the relevant (neu‐
ro)chemistry of the selected organ and how it relates to the tracer to be used. In a simple
conception of the brain, we must include the vasculature that delivers the tracer to the tissue.
The blood brain barrier – how does the tracer traverse it? Once inside the tissue, are there
receptors or transporters to (specifically) bind the tracer? If there are multiple possible specific
binding sites, is there one site that is likely to dominate? Inevitably there will be nonspecific
(i.e., non-displaceable) binding as well, because there are other entities in the tissue that appear
to retain foreign molecules. Due to mathematical limitations (related to the limits of parameter
identifiability), most models will treat the nonspecific binding pool as a sub-pool of the free,
unbound tracer; nevertheless, we must keep in mind that such a process lurks under the surface
even if it is not explicated in the model statement. Next, we must conceptualize the possible
fates of the tracer into distinct pools or compartments of the model (all compartments are pools,
but not all pools are compartments – see next section for explanation). Every route by which
tracer can move from one compartment to another must be assigned a rate constant (designated
by an arrow in Figure 11c). Finally, we turn a diagram of connected pools into a series of
equations. Because what drives movement of tracer is mass action (diffusion from pools of
high concentration to low), we must write mass balance equations for each compartment. Mass
balance equations assert that the net accumulation of tracer over time is equal to the amount
of tracer coming into the compartment per time, minus the amount of tracer leaving per time,
plus tracer generated, minus tracer destroyed. Typically, generation does not apply – our
bodies do not create exogenous compounds. These equations take the form of ordinary
Paired Bolus design Bolus plus Infusion design
order of conditions can be randomized: baseline/
challenge requires no model-fitting to estimate BP, ΔBP
requires two successful syntheses requires only one successful synthesis of tracer
studies with [18F]-labeled tracers require two separate
scan days; more chance of physiological variability requires computerized injection
(high- and low-binding) regions don’t all reach equilibrium
at same time.
requires that regions of interest reach equilibrium; data
may be unusable if equilibrium is not achieved
B/I scan needs more radioactivity than single bolus scan
Table 1. Experimental Design. Some common advantages (blue) and disadvantages (red) of paired bolus and bolus
plus infusion designs for measuring drug-induced changes in the neurotransmitter levels with PET.
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differential equations. The only dependent variable is time. The dependent, or “state”,
variables are the unknown concentrations in the respective compartments.
Figure 11. Schematic of the tracer kinetic modeling process. (a) Identify an organ of interest and a region of interest
within it. (b) Consider the relevant physiology or biochemistry. (c) Abstract the tracer pools into connected compart‐
ments. (d) Write the mass balance equations
1.2.11.2. Compartmental models (1T, 2T)
Compartments represent the unknown variables of a model (free tracer, F, bound tracer, B).
These are sometimes referred to as “state” variables. Although in most circumstances plasma-
borne tracer can be thought of as a distinct “pool”, we typically do not assign it a compart‐
ment, because it is measured directly via an arterial catheter and therefore not an unknown.
Rather, the plasma tracer concentration over time is an input to the system. That is the case for
the two most common compartmental models used to describe PET tracers: the one-tissue
compartment (1T) and the two-tissue compartment (2T) models (see Figure 12). Each of these
models requires measurement of the arterial plasma concentration of tracer as the input function.
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Arterial blood taken from the arm is considered a good representation of the tracer concentra‐
tion in arterial blood reaching the brain at each moment in time. For tracers that are known to
bind specifically to a target, it would seem natural to model them with the 2T model. Howev‐
er, the 2T model has 4 unknown parameters: K1, k2, k3, k4. By contrast, the 1T model has one
variable, the concentration of tracer in the tissue and only 2 parameters, K1 and k2 1T. Note that
the k2 parameters have different meanings for each of the two models and so in this chapter, we
give them different superscripts to distinguish between them (the reader is advised that this is
typically not done in the PET literature). While the 2T model would seem the intuitive choice –
especially if we know that specific binding of tracer to a target occurs - it is not always support‐
ed by the data. That is, the specific binding may be too fast to allow for reliable estimation of k3
and k4 or it represents only a small fraction of the total uptake or perhaps the signal to noise
ratio of the data is poor. Whatever the reason, if we cannot uniquely identify all the parame‐
ters of the 2T model by fitting it to the data, the 1T model can be used and the total volume of
distribution, Vt = K1/k2 1T, becomes the estimated endpoint. By contrast, Vt as measured with the
2T model is defined as Vt = K1/k2 2T(1 + BP). If the Vt is estimated from parameters of the 1T model,
but specific binding exists, then k2 1T implicitly contains effects of the specific binding term, BP.
Figure 12. Common compartmental models used to analyze PET TACs. 2T model (top) has 2 unknown variables and 4
parameters (rate constants) to be estimated from the data. 1T model has only one variable (the tissue compartment)
and 2 rate constants to be estimated.
1.2.11.3. Graphical methods
To fit TACs with the 1T or 2T models requires an iterative algorithm and some knowledge of
numerical methods, parameter estimation, and computer programming. There is a popular
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alternative to iterative curve fitting that can be used in many circumstances. Collectively, these
methods are based on rearrangements of the model equations to yield linear relationships
between measured quantities (Ichise et al., 2003; Logan et al., 1996; Logan et al., 1990; Patlak
et al., 1985; Patlak et al., 1983; Zhou et al., 2006). One can think about these methods as
transformations akin to a logarithm that transforms an exponential relationship into a linear
one. The Logan plot was the first linearization of the 2T model to be applied widely to
reversibly bound tracers (e.g., [11C]raclopride). The slope of the original Logan plot is
equivalent to the volume of distribution, Vt, the same parameter that can be estimated directly
with either the 1T or 2T model (Logan et al., 1990). An advantage of using the Logan plot is it
is possible to perform all the necessary calculations in a spreadsheet. Further, the estimate of
Vt via the Logan plot is highly robust. That is, it almost never fails to produce an estimate with
high precision. A disadvantage of the Logan plot is that it is not unbiased. It has been shown
to underestimate Vt with increasing noise in the PET data (Slifstein et al., 2000). As with proper
experimental design, one must be cognizant of potential biases that can be introduced into the
analysis by the model or the model transform and guard against misinterpretation.
1.2.11.4. Reference region methods
From the diagrams in Figure 12, it would appear that one always needs a measured plasma
input function to drive a kinetic model. On its face, this makes sense, since tracers enter (are
inputted) into the system via the plasma. In fact, models designed to describe the data in the
tissue can also work with input functions derived from reference regions in the image. A
reference region is one that is essentially equivalent to the target region except that it is devoid
of specific binding sites. By taking advantage of the fact that the same plasma concentration
of tracer supplies both the target and the reference regions, it is possible to eliminate the plasma
concentration from the model and describe the concentration in the target region compart‐
ments in terms of the reference region concentration. In effect, the reference region has become
the input function. This concept was first applied to PET data by Farde et al. and by Cunning‐
ham et al. (Cunningham et al., 1991; Farde et al., 1989). Subsequent assumptions applied by
Lammertsma and Hume reduced the number of parameters in the reference tissue model (thus
named the “simplified reference tissue model” (SRTM)) (A. Lammertsma et al., 1996; A. A.
Lammertsma et al., 1996). Finally, Gunn et al. devised an implementation of SRTM (using basis
functions) that turned it into a linear model and thus almost as easy to use in practice as the
Logan plot (Gunn et al., 1997).
1.2.12. Physics basics
The spatial precision of PET is based on the concept of “electronic collimation”. That is,
radioactive decays lead to pairs of 511KeV photons being emitted in (nearly) opposite
directions. When they are captured simultaneously by detectors in the PET scanner ring, a
coincidence is recorded. Because of the co-linearity of the paths of the two photons, the
direction from which they came is known and physical collimators (used to filter out photons
approaching at various angles to the detector) are not needed. The sequence of coincidence
detection is diagrammed in Figure 13. But there are certain common ways that electronic
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collimation can be foiled and standard corrections must be applied to the raw data to assure
that the emission images are quantitative and proportional to concentration of tracer. Some





Figure 13. (top left) A positron emitter emits a beta particle. (top right) Beta particle annihilates with an electron and
two photons are produced which exit the object in opposite directions. (bottom left) The two 511 KeV photons are
detected by opposing detectors, leading to signals being recorded. Coincidence logic determines that the events hap‐
pened within a pre-set time window. The time of the coincidence event and its unique angle, Φ, and distance, R, are
recorded. (bottom right) Image reconstruction locates the original annihilation event along a line-of-response (within
the dotted lines).
1.2.12.1. Scatter
If either pair of photons emanating from a single annihilation event is deflected from its path
but still detected simultaneously with the non-deflected photon, then the positioning of the
line of response (between the two detectors) will be incorrect.
1.2.12.2. Randoms
If one photon each from two separate annihilation events is lost to attenuation or scatter and
the remaining photons (from different events) are detected simultaneously, the apparent
coincidence event will be located improperly.




If the amount of radioactivity in the object is so great that the rate of annihilation events exceeds
the capacity of the detectors to record them, then annihilation events will be lost. This condition
threatens the quantitative value of PET. We assume that detected coincidences are proportional
to concentration of radiotracer molecules in the object. If the detectors are “maxed out”, then
this desired linear relationship no longer holds and the images are no longer quantitative.
Commercial PET scanners typically come with reconstruction software that corrects for scatter,
randoms, and deadtime.
1.2.12.4. Positron range
When a beta emitter ejects a beta particle, the particle travels some finite distance before
annihilating with an electron. The two 511 KeV photons that result from the annihilation are
  
Figure 14. (a) Scatter: A collision of one of the daughter photons with scattering material disrupting the normal co-
linearity of the photon paths but not their ultimate detection leads to a mis-placement of the line of response (grey
start). (b) Randoms: if single photons are absorbed or otherwise not detected, unrelated pairs of photons can be de‐
tected as a coincidence leading to a mis-location of the originating event (grey star). (c) Dead Time: if too much radio‐
activity is in the object such that detectors cannot keep pace with decay events, then information is lost and
radioactivity is no longer proportional to tracer concentration. (d) Positron Range: notice that the relocation along a
line of response is never tied to the tracer molecule but rather the annihilation even though, in fact, we seek to locate
tracer molecule itself. The positron range of a beta particle is inversely related to its energy and represents an unavoid‐
able blurring of the image from ideality.
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thus emitted from a location that is some distance from the location of the tracer molecule that
we seek to localize. This distance, called the positron range, is an average distance that is
dependent on the energy of the emitted beta (see Table 2). Positron range contributes uncer‐
tainty to the localization of the deposited radiotracer. Because it is not directional (equally
likely for beta to travel in any direction), the positron range contributes a blur to the image.
T ½ Photon               Positron Nuclide (min)            Energy Energy Range
(keV)                        (MeV)      (mm in H20)
15O 2.1 511 1.70 1.5
13N 10.0 511 1.19   1.4
11C 20.3 511 0.96 1.1
18F         109  511 0.64 1.0
Table 2. Beta energies for common PET isotopes and their positron range
1.2.13. Attenuation correction
Without attenuation correction, regions of an object near its outer surface would appear hotter
than regions deep inside because photons emerging from within a body are more likely to be
scattered or absorbed and not detected than those starting on or near the body’s surface. Data
from a CT scan or model can correct non-uniform attenuation in the brain.
1.2.13.1. Attenuation correction artifacts
A lot of work has gone into improving attenuation correction for whole body images. Consider
PET images of the chest. There are large translations of the chest from the beginning to the end
of the normal respiratory cycle. Unlike CT imaging which is very fast, we cannot ask subjects
to hold their breath for 10 minutes while we acquire an FDG-PET scan of their torso. In fact,
the development of PET/CT (two scanners integrated together) was driven in part by the need
to have multiple attenuation scans for different phases of the respiratory cycle. Kinahan and
colleagues have shown – quite persuasively – that failure to align the transmission scan to data
from separate ‘gates’ (images acquired in different phases of breathing, gated -or triggered -
by the respiratory signal) causes serious artifacts on images of the chest (Liu et al., 2009). These
artifacts can be so serious that they can be mistaken for tumors (Liu et al., 2009) or as serious
defects in cardiac perfusion (Alessio et al., 2007). Alessio et al. showed that perfusion was
underestimated by 60% if the attenuation map was misaligned due to normal respiration
(Alessio et al., 2007).
Generally, a skull does not expand and contract like a chest (due to respiration), so a single
transmission scan taken at the beginning or end of a PET scan session is adequate for attenu‐
How to Study Smoking and Drinking with PET
http://dx.doi.org/10.5772/57414
121
ation correction of brain images. However, this may not be the case for certain types of studies
of drug taking (reviewed below). In these cases, the act of taking a subject out of the scanner
and then re-positioning them following drug administration could potentially lead to a
mismatch between the transmission scan (taken at start of session) and the PET images
acquired after the re-positioning.
2. PET Imaging of drug challenge studies
Here, we discuss a series of parameters or conditions that make it challenging to use PET to
image receptor changes and drug-induced changes in the human brain. These themes will be
repeated throughout the remainder of the chapter as they arise in the discussions of the
literature.
2.1. Novelty
Many different imaging groups measure drug-induced changes in dopamine release in the
scanner or during the study day. However, dopamine is released in response not just to drugs
of abuse but also to stress and to novelty. As the majority of subjects in these studies will not
have been exposed to these experimental situations in their past, the experience will be novel
to them. Suffice to say, it would not be helpful to be imaging novelty-induced dopamine release
when one is trying to measure the effect of a drug. One way to avoid this common confound
is to expose the subject to the study environment before their participation begins. In the case
of our smoking-in-the-scanner studies, we have the subjects lie down in the scanner and
simulate smoking at a session prior to a real scan session.
2.2. Order effects
Order effects can occur in any scientific study. In rodent studies of drug treatment when a
placebo is compared to an active drug, the conditions are counter-balanced so that some rats
receive the drug first and other rats receive the placebo first. This eliminates bias that could
occur if the order in which drugs were given were to alter the results. In imaging studies, this
can be more challenging. When using radiotracers with short half-lives (carbon-11 has a 20.3
minute half-life), it is possible and sometimes preferable to do baseline and drug-challenge
scans on the same day. This can reduce the variation between scans that may occur if scans are
conducted far apart in time. It also increases the likelihood that the subject will be able to easily
complete the study (e.g., it is usually easier for a subject to commit to one day at the PET center
rather than having to take off multiple days from their job or school). However, this also makes
it more difficult to randomize the order of scans.
Consider scans of amphetamine-induced dopamine release. Amphetamine’s effect on dopa‐
mine (and thus 11C-raclopride binding) is profound and long-lasting. It is not possible to do
the drug-challenge scan on the same day before the baseline scan, since the effect of amphet‐
amine would persist for hours (possibly longer) and corrupt a subsequent “baseline” meas‐
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urement. On the other hand, if effects of a drug or other stimulus are short-lived, it is generally
possible to counter-balance the scans.
2.3. Expectation and reward-prediction error
We can learn from the work of Shultz and colleagues that dopamine neurons not only are
activated in the presence of most drugs of abuse but that they are activated even before delivery
of a drug, in response to cues and other stimuli that are “conditioned” or a conditioned
stimulus (CS) (Schultz et al., 1997). Additionally, the dopamine neurons are sensitive to
changes and errors in reward, which can be called prediction error. Dopamine neurons in the
nonhuman primate brain fired after presentation of a reward that was not paired with a CS.
When the reward and CS were paired, the dopamine neurons fired in response to the presen‐
tation of the CS and not to the subsequent presentation of the reward (Figure 15). That is, the
dopamine neurons activated to the CS itself, because it was predictive of a reward (Doyon et
al., 2005; Doyon et al., 2006). When the CS is presented and then the reward does not occur
(negative prediction error), there is the typical activation to the CS, but then a dip in dopamine
neuron activation when the expected reward does not occur. This study highlights how
sensitive the dopamine system is to cues and expectation of reward, and care needs to be taken
to design PET studies that take this sensitivity into account.
2.4. Sex differences
Sex differences are evident in many psychiatric disorders, medical disorders, and also in the
normal human brain (Cosgrove, Mazure, et al., 2007). There are sex differences in structure
(e.g., total volume of the human brain and some subdivisions), in function (e.g., emotional
processing as measured with fMRI), and in chemistry (as measured with PET). These differ‐
ences are important to measure, as they may clarify the clinical literature. It might be helpful,
for instance, to know if the higher prevalence of depression in women vs. men can be explained
by greater serotonergic dysfunction in women. Unfortunately, sex differences can also cloud
the interpretation of data - if they are not carefully recognized and controlled. In one of our
own studies, we were at first convinced of differences in nicotinic Acetylcholine receptor
(nAChR) availability between healthy men and women when looking at a standard imaging
outcome measure, volume of distribution (VT). On further examination, however, we also
found significant differences in total parent of the radiotracer (total unmetabolized radiotracer
in the blood) and in fp (the fraction of radiotracer free in the blood and not bound to plasma
proteins). When these two factors were included in the analysis (by use of the normalized
outcome, VT/fp), the apparent sex difference disappeared (Figure 16) (Cosgrove, Mitsis, et al.,
2007).
2.5. Patient management
Care must be taken in managing any study with human subjects, especially patients who are
not typical healthy controls but may be individuals suffering from psychiatric disorders. There
is a balance that must be struck between designing a study to answer every possible experi‐
mental question and keeping the demands on the participants within reason. As described
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Figure 15. (Top) Prior to conditioning, reward without prediction causes a positive error in reward prediction, which
increases DA neuron firing. (Middle) Following conditioning, the CS predicts the reward, leading to no prediction er‐
ror. CS but not reward shows increase in DA neuron firing. (Bottom) After conditioning, CS but no reward causes a
negative error in reward prediction. The CS causes increase in DA neuron firing, but the lack of reward causes a DE‐
CREASE in DA firing (Schultz et al., 1997).
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below, in many smoking studies we asked our subjects to quit smoking. If this is for a short
time, the subjects can manage. When it is for longer, we must implement strategies to help
them quit. When we asked schizophrenic smokers to quit smoking, we took the additional step
of having them stay in an inpatient facility for the week so they could be monitored.
There is also a huge effort that goes into subject recruitment and screening before individuals
are invited to participate in studies. Subjects undergo batteries of psychological tests, thorough
medical evaluations including a physical exam, complete blood tests, drug toxicology tests,
electrocardiograms to ensure cardiac health, and structural MRs to rule out any obvious brain
abnormalities. There is also a lengthy informed consent process that must be conducted with
all potential subjects. SPECT and PET studies are complex and may involve a variety of risks
including administration of radiotracers, placement of arterial lines, and drug administration.
Each facet of the study demands discussion between investigator and subject of the potential
risks. All of our studies are carefully evaluated and approved by a local radiation safety and
a human subjects investigation committee (the latter is typically referred to as an Institutional
Review Board or IRB).
Figure 16. Mean parametric images illustrating 1231-5-IA-85380 activity in 10 men and 19 women in VT’ (regional ac‐
tivity divided by total plasma parent between 6 and 8 h) and VT (regional activity divided by free plasma parent be‐
tween 6 and 8 h). Across brain regions, the main VT’ component was significantly greater in women than in men, but
the main VT component did not significantly differ between the sexes. This research was originally published in JNM.
123I-5-IA-85380 SPECT Imaging of Nicotinic Acetylcholine Receptor Availability in Nonsmokers: Effects of Sex and
Menstrual Phase. JNM. 2007;48:1637. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.
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Brody (2004) Brody (2006) Barrett (2004) Scott (2007)
Tracer [11C]raclopride [11C]raclopride [11C]raclopride [
11C]carfentanil &
[11C]raclopride
Injection protocol Bolus + infusion Bolus + infusion Bolus Bolus + infusion
Tracer dose Slow bolus injection 5 mCi,followed by infusion 3mCi/hr
Slow bolus injection 185
MBq, followed by
infusion 111 MBq/h
10 mCi in 10 ml saline
over 120 seconds 10-15 mCi
Scanner
(resolution) ECAT 953 (5.6 mm FWHM) GE Advance NXi
ECAT HR+ (42 mm
FWHM)
Siemens HR+ (~5.5 x 5.0
mm FWHM)
Design Inter-subject (1 scan) Inter-subject (1 scan) Intra-subject (2 scans) Intra-subject (2 scans)
Analysis Equilibrium Equilibrium SRTM Logan Ref
Phenomenon to
test
DA release in ventral striatum
due to smoking
Gene variants of DA
pathway & smoking
DA release due to
smoking and hedonic
response
μ-opioid and DA D2
receptors and nicotine












• 15-40 cigarettes per
day
• No overlap with
previous study group





cigarette 2 hrs 3 hrs Minimum 12 hrs ~12 hrs
Protocol
During the scan, subjects had a
10 min break OUTSIDE scanner;
10 smoked 1 cigarette; 10
controls
During the scan, subjects
had a 10 min break
OUTSIDE scanner; 35
smoked 1 cigarette; 10
controls
2 scans, 1 control and 1
smoking; smoked in








Timing 10 min break (smoking or not)50 min post scan initiation




Cigarette 15 min pre
[11C]raclopride; aimed to
smoke 1 cig / 12 min,
max. 6 cigs
90 min scans; smoked
each cig for 5 min;
smoke denicotinized cig
at 2 & 12 min; smoke
avg. nicotine cig at 40 &
50 min
Self admin. Yes, outside scanner Yes, outside scanner Yes, in scanner Yes, in scanner
Cigarette type Usual brand Either usual brand orstandard study cigarette Usual brand
Denicotinized & average
nicotine
Ventral striatum -4.3 ± 1.4% 3.12%
Putamen • Left -36.6%• Right -29.7%
• Anterior 2.9%
• Posterior -1.59%
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Brody (2004) Brody (2006) Barrett (2004) Scott (2007)
Caudate / N Acc • Left -30.5%• Right -25.9% -8.4 ± 13.8% -1.9%
Basal ganglia 9.98%
Concerns
• Going outside for no-
smoking group can still be a
cue
• Not the first cigarette of the
day, perhaps not a strong
response.
• CT only done prior to break,
not after return to scanner-
possible attenuation issues
• Figure 2: 2 subjects driving
the effect?
• Table 2: baselines are not the
same in groups (smoking
group higher in all regions,
although not significant)
• Only one attenuation
scan (following the
return to the scanner)
was applied to both the
pre and post break scans
• Some subjects smoked
favorite brand, some
smoked study standard
cigarette • Only 10
controls vs the 35 that
smoked
• Not all subjects smoked
the same number of
cigarettes




• Large range of ∆BP in
smoking group (ventral





• Novel use of Logan
graphical analysis to
detect change in slope –
not published elsewhere.
Table 3. Smoking Studies
Salonen (1997) Boileau (2003) Urban (2010) Yoder (2009) Oberlin (2013)
Tracer [11C]raclopride [11C]raclopride [11C]raclopride [11C]raclopride [11C]raclopride
Injection
protocol Bolus Bolus Bolus + infusion Bolus Bolus
Tracer dose 2.89 – 3.51 mCi 10 mCi ~ 7.8 mCi 14.1 ± 0.99 mCi 14.9 ± 0.10 mCi
Scanner
(resolution)
ECAT 931 (6.1 X 6.7
mm)
ECAT HR+ (4.8 x 4.8
x 5.6 mm FWHM) ECAT EXACT HR+
EXACT HR+ (9 mm
FWHM)
EXACT HR+ (9 mm
FWHM effective res.)
Design Intra-subject (2 scans)Intra-subject (2scans)
Intra-subject (2











Alcohol & alcohol cues Beer flavor induced DArelease

















Non drug or alcohol
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Salonen (1997) Boileau (2003) Urban (2010) Yoder (2009) Oberlin (2013)
Time from last
drink ~12 hrs 24 hours Since night before ~24 hours ~48 hours
Protocol
• Drink BEFORE scan
• 2 scans: 1) placebo,
2 hr break, 2) ethanol
Drink BEFORE scan,
not told content of
drink until this time
Scan order
randomized













3 separate drinks of
placebo (75, 65, 55
min pre bolus), bolus,
scan; 2 hr break;
same schedule
except using ethanol
Drink for 15 min,
30 min prior to
bolus
Drink for 5-10 min,
5 min prior to bolus
+ infusion
Neutral or alcohol cues
start 2 min after bolus,
maintained 15 min
Beer or Gatorade flavor






Self Self Self Investigator (IV infusion) N/A
Alcohol type
Orange juice plus








Ringer’s lactate with or
without alcohol N/A
Ventral
striatum 16.8 ± 16.3%
• Men: -12.1 ± 8%
• Women: -6.2 ±
8%




condition: 0.12 ± 0.08
• R ventral striatum:
• FH+: 11.7 ± 4.1% (SE)
• FH (ambig.): 3.8 ±
2.5%
• FH-: 2.7 ± 2.7%
N. acc. 15.0 ± 15.9%
Putamen No significantdifference:
5.2 ± 17.5% Ventral
13.7 ± 17.5%
Caudate -0.10 ± 0.12 (P = 0.43)4.0 ± 16.4%
Concerns
•Alcohol taken long




nauseous to have > 1
drink)
•Alcohol taken




alcohol – may have
been aversive








• No conditioning to
cues (ala Shultz et al
997). Study assumes that
cues are salient.
• Only FH+ subjects
showed effect of beer
flavor on DA





Table 4. Alcohol Studies
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Weerts (2008) Weerts (2011)
Tracer [11C]carfentanil & [11C]methyl naltrindole [11C]carfentanil & [11C]methyl naltrindole
Injection protocol Bolus Bolus
Tracer dose [
11C]CAR (19.4 ± 2.1 mCi); [11C]MeNTI (19.2 ± 3.2
mCi)
Avg. mCi: [11C]CFN: 19.30 (AD), 19.99 (HC); [11C]MeNTL:
18.87 (AD), 17.52 (HC)
Scanner




Naltrexone occupancy of δ- and μ- opioid
receptors δ- and μ- opioid receptor availability at baseline
Subjects 21 alcohol dependent & healthy control (15male, 6 female) 25 alcohol dependent & 30 healthy control
Subject
characteristics
60+ drinks/month, at least 5 drinks/occasion
weekly
DSM-IV criteria for alcohol dependence; controls <8
drinks/wk women, <15 for men
Time from last
drink 15 days prior to naltrexone treatment 5 days
Protocol 15 days abstinence, followed by 4 daysnaltrexone
2 PET scans in fixed order on the same day: [11C]MeNTL
followed by [11C]CFN
Timing 19 days inpatient, 50 mg p.o. 2x on day 15, then1x daily for remainder of days; scan day 5 days inpatient protocol; scans on day 5
Mode of alcohol
administration N/A N/A
Alcohol type N/A N/A
Ventral striatum All ROIs:[11C]CAR: 94.9 + 4.9% occupancy
• AD = 1.826 ± 0.068
• HC = 1.438 ± 0.061
Putamen
[11C]MeNTI: 21.1 + 14.49% occupancy
• AD = 1.272 ± 0.044
• HC = 0.962 ± 0.040
Caudate • AD = 1.395 ± 0.057• HC = 1.113 ± 0.052
Table 5. Weerts Studies of Alcohol Dependence
3. Preclinical imaging of nicotinic acetylcholine receptors
3.1. Using nonhuman primate studies to aid in design of human studies
3.1.1. Wash-out of nicotine in the brain
One key way that nonhuman primate (NHP) studies can help us to inform our clinical studies
is to work out basics of experimental design before we inject radiotracers into humans. For
imaging studies we conducted with the goal of measuring nicotine-induced “upregulation”
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of nAChRs in humans, preceding NHP studies played a critical role in experimental design.
There is a wealth of literature showing that nicotine and tobacco smoking upregulate nAChRs
throughout the brain (Abreu-Villaca et al., 2003; Breese et al., 1997; Kassiou et al., 2001; Marks
et al., 1992). Nicotine studies with various doses and routes of administration to rats, mice, and
monkeys - as well as postmortem human studies – have all demonstrated that nicotine and
tobacco smoke result in significantly more nAChRs throughout the brain compared to saline
(animals) or to not smoking (humans). We now know that nicotine itself is responsible for this
upregulation. Nicotine acts in the cell to help the receptor subunits assemble and then acts to
chaperone the receptors to the cell membrane (Srinivasan et al., 2010). Our goal was to measure
this upregulation in living human tobacco smokers (Staley et al., 2006). But first, we needed to
work out the proper experimental timing.
Nicotine and our radiotracer, [123I]5-IA-85380, both bind to the same receptor in the brain – the
nAChR containing the β2-subunit. When nicotine is present in the brain, it blocks the receptor
and prevents the radiotracer from binding. Our preclinical experiment consisted of two
monkeys drinking nicotine (diluted in water and sweetened with Tang to make it more
appetizing) for 6 weeks. After 6 weeks, the monkeys were taken off nicotine. One monkey was
scanned at 1 day into nicotine withdrawal, and the other was scanned at 2 days into nicotine
withdrawal. Surprisingly, the data showed a decrease in radiotracer binding - suggesting that
receptors may have been down-regulated! To probe further, we put the monkeys back on
nicotine for two weeks and then scanned them both at 7 days of withdrawal. At that point, we
saw the robust increase in radiotracer binding that was suggested by the preclinical literature.
Taken together, the early data and the 7-day data suggested that nicotine remains in the brain
during early withdrawal, and one must wait about 7 days for it to clear before measuring
nicotine-induced upregulation. We also measured urine cotinine (the major metabolite of
nicotine) levels in the monkeys over the 7 days of withdrawal. Cotinine progressively declined
over the week, not completely clearing or reaching nonsmoker levels until 7 days of abstinence.
The cotinine data nicely mirrored the brain closely. Once cotinine had cleared, we knew that
we could proceed to measure nicotine-induced upregulation of nAChRs in the brain. In our
human studies, discussed below, we routinely use low cotinine levels as an indicator that
nicotine has cleared and that smokers can be scanned for nAChR.
3.1.2. Simplifying the analysis of nAChR availability
As described in the Introduction, a reference region simplifies the estimation of receptor
availability. β2-nAChRs are widely distributed throughout the whole brain with highest
density in the thalamus, moderate binding in the cerebellum, striatum and brainstem, and low
binding throughout the cortex. There is no region in the brain completely devoid of β2-
nAChRs, so there is no appropriate reference region. For many of the studies imaging β2-
nAChRs with SPECT or PET described herein, a bolus plus constant infusion paradigm was
used to achieve equilibrium between the brain and the blood (see Section 1.2.10.1). The
outcome measure was volume of distribution, VT, which can be calculated as concentration of
radioactivity in brain divided by concentration of radioactivity in blood, provided an equili‐
brium has been achieved between tissue and blood concentrations of tracer. VT is related to
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binding potential (BP) and can be used as a measure of receptor availability. Because the bolus
plus constant infusion paradigm in these studies reliably achieves equilibrium, the analysis is
simplified, and there is no need for kinetic modeling. We refer to our outcome measure as
receptor “availability”, because we are not measuring all receptors. We cannot measure those
receptors which, on average, are occupied by the endogenous neurotransmitter, acetylcholine,
or by an exogenous ligand such as nicotine (hence the unexpected results at day 1 of with‐
drawal) (Staley et al., 2006).
3.1.3. Human nAChR scans in tobacco smokers
Based on the preclinical monkey studies, our group imaged β2-nAChRs in human tobacco
smokers at 7-9 days of smoking abstinence (‘withdrawal’). In these studies, the subjects were
required to quit smoking and not use any medications or nicotine replacement strategies such
as the patch, because all forms of nicotine would bind the β2-nAChR and block the radiotracer
from binding. In order to help the subjects quit smoking, we used contingency management
(Staley et al., 2006). Put simply, subjects met with a member of the research group one to two
times per day and gave evidence that they had not smoked. ‘Evidence’ is established by carbon
monoxide breath readings less than 11 parts per million (the level of a nonsmoker) and urine
cotinine levels that are at the level of a nonsmoker or decreased from the day before. Contin‐
gent upon successful tests, subjects are paid small sums of money, and they can typically earn
up to $230 for abstaining for up to 9 days. In other words, we used positive reinforcement to
help the subjects maintain abstinence for the duration of the study. In our first paper, we
demonstrated that tobacco smokers at 7-9 days of abstinence have significantly higher β2-
nAChR availability in the cortex, striatum, and cerebellum compared to a group of age- and
sex-matched nonsmokers (Figure 17). This work confirmed that it is possible to measure the
upregulation phenomenon in human smokers, in vivo (Staley et al., 2006).
There is also evidence from preclinical and postmortem studies that the β2-nAchRs do not stay
upregulated but return to control levels. A postmortem study indicated that smokers who had
quit smoking at least two months prior to their death had β2-nAChR levels similar to controls
(Breese et al., 1997). However, smokers in the study had quit anywhere from 2 months to 30
years prior to their death, so the study did not shed light on the acute time course of receptor
changes, e.g., during acute withdrawal in the first few months of abstinence. In our next study,
we imaged β2-nAChR changes over the first few months of abstinence in tobacco smokers
(Cosgrove et al., 2009). As shown in Figure 17, at one day of abstinence, nicotine is still present
in the brain blocking the receptor, and there is no difference in β2-nAChR availability com‐
pared to the group of nonsmokers. At one week of abstinence, we again demonstrate there is
higher β2-nAchR availability in smokers compared to nonsmokers. Then even at 2 and even
4 weeks of abstinence, receptor availability remains high and does not return to nonsmoker
control levels until 6-12 weeks of abstinence. This study demonstrates that upregulation of β2-
nAChRs is persistent, and these brain changes during acute abstinence are consistent with the
clinical course of smoking cessation in which craving, relapse, and withdrawal symptoms
occur over the first few months of abstinence, and relapse may occur months or years after the
last cigarette. It is possible that nicotine replacement strategies are effective in some people,
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because they continue to activate the pool of upregulated receptors and help “wean” the
receptors off of nicotine as the dose of nicotine is decreased over time.
There is a large literature demonstrating sex differences in tobacco smoking behaviors. In
general, men tend to smoke for the nicotine reinforcement, or nicotine per se in the cigarette,
whereas women tend to smoke more for the sensory cues associated with smoking, as well as
affect and stress regulation (Perkins, 2009; Perkins et al., 1999; Perkins et al., 2008). There are
also two preclinical studies showing that male rats and mice exposed to nicotine exhibited
greater nAChR upregulation than female rats and mice exposed to nicotine (Koylu et al.,
1997; Mochizuki et al., 1998). We wanted to determine if there were sex differences in β2-
nAChR availability between men and women smokers compared to nonsmokers. Consistent
with the preclinical literature, we found that male smokers had significantly higher β2-
nAChRs compared to male nonsmokers (between 9 and 17%) but that women smokers had
similar β2-nAChR availability compared to women nonsmokers (between 1 and 3 %)
(Cosgrove et al., 2012). This was a striking finding given all the studies demonstrating that
nicotine and tobacco smoking upregulate β2-nAChRs throughout the brain. Considering
known behavioral sex differences in tobacco smoking, these findings make sense and provide
Figure 17. β2-nAChR availability (VT/fP) is shown in individual nonsmokers (open diamonds) and tobacco smokers (fil‐
led circles) at 1 day, 1 week, 2 weeks, 4 weeks, and 6-12 weeks of abstinence in the thalamus, striatum (average of
caudate and putamen), cortex (average of cortical regions including parietal, frontal, anterior cingulate, temporoinsu‐
lar, and occipital cortex), and cerebellum. The line in each scatter plot represents the mean value of those subjects. *
indicates significant difference from control nonsmokers after Bonferroni’s correction using two-sample t-tests. † indi‐
cates significant difference from 1 week abstinent smokers after Bonferroni’s correction using planned post-hoc be‐
tween-group comparisons subsequent to the analysis of repeated measures mixed-effects regression models
including the overall effect of abstinent smoker group.
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a biological mechanism that may underlie some of the behaviors. Specifically, men smoke for
the nicotine in cigarettes, they are more responsive to nicotine replacement therapy as a
cessation strategy, and men’s brains are responsive to nicotine, exhibiting upregulation of β2-
nAChRs. Women smoke for affect regulation and for reasons other than the nicotine, they do
not respond as well to nicotine replacement strategies, and their brains do not respond to
nicotine by increasing β2-nAChRs. The bottom line is that novel treatment strategies targeting
other receptor systems need to be evaluated to more effectively help women quit smoking. All
the current strategies act at the β2-nAChR, and, of course, all nicotine replacement strategies
act at that site. Varenicline (Chantix) is a partial agonist at the β2-nAChR, and even bupropion
(Zyban) is a nicotinic antagonist.
In addition to receptor changes, imaging studies have informed our knowledge about what
happens in the brain after someone smokes a cigarette. For example, after one puff of a
cigarette, approximately 50% of all β2-nAChRs in the brain are occupied by nicotine. After
smoking one or two cigarettes, the receptors are saturated, so 100% of β2-nAchRs are occupied
by nicotine (Brody, Mandelkern, London, et al., 2006). We know that nicotine doesn’t clear the
brain right away, so if all the receptors are occupied by nicotine, why do people keep smoking
throughout the day? This brings up some important points about tobacco smoking. People
smoke for many different reasons, and nicotine reinforcement is only one component. The
reinforcement or pleasure derived from nicotine, like many other drugs of abuse, is necessary
in driving the initial phases of drug seeking behavior. But as the addiction progresses, many
people continue to smoke in order to avoid withdrawal symptoms and due to the many
conditioned cues that have become ingrained, which are a part of the repetitive nature of
tobacco smoking. Additionally, there are 4000 chemical compounds that are produced when
a cigarette burns; all of these compounds are in tobacco smoke and are inhaled. Thus, while
nicotine is the primary addictive component of tobacco smoke, there are additional com‐
pounds such as MAO-A and MAO-B inhibitors that likely play a role.
Other imaging studies have demonstrated that even smoking a denicotinized cigarette, which
supposedly has very low nicotine content, still occupies up to 20% of β2-nAChRs in the brain
(Brody et al., 2008). This is similar to the level of occupancy produced by second hand smoke.
Dr. Arthur Brody and colleagues at UCLA performed an elegant study examining the effect
of second hand smoke on β2-nAChRs by having subjects sit in a car (the window was down
a few inches) with a person smoking, and they reported up to 20% of β2-nAChRs were
occupied by nicotine in the individual who was just sitting in the car, not smoking (Brody et
al., 2012). Interestingly, a recent law in California prohibits smoking in the car with children
under the age of 18.
3.1.4. Use of microdialysis measurements
Before PET made possible indirect measurement of dopamine release, in vivo, the only way to
measure dopamine levels in a living brain was via microdialysis. Microdialysis is used
primarily in rodents. During a surgery, a probe is placed through the skull into the region of
interest, e.g., the nucleus accumbens. After recovery, dopamine levels can be sampled in the
awake, behaving animal typically in response to a drug or a stimulus. Di Chiara and Imperato
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performed the seminal study showing that drugs abused by humans release DA in the nucleus
accumbens of the rat brain using this technique (Di Chiara et al., 1988). Amphetamine (1.0 mg/
kg, SC) raised DA levels over 1000% from baseline, whereas ethanol (1.0 g/kg, IP) and nicotine
(0.6 mg/kg, SC) raised DA levels to 200% over baseline levels. This illustrates how powerful
DA release can be when it is directly stimulated as with amphetamine, which is both a direct
DA releaser and DA reuptake inhibitor. Put into context, a similar dose of amphetamine given
to a monkey or a human in a PET experiment, which is an indirect measure of change in DA,
would result in a 15-30% change in BP as measured with [11C]raclopride or another D2/3 ligand.
4. Imaging dopamine release in response to nicotine, tobacco smoking, and
alcohol in humans
As we have recounted, one natural strategy for using PET and SPECT to study smoking has
been to image nAChR directly with a nicotinic ligand. Such studies have led to greater
understanding of nicotine’s persistence in the brain, sex differences in nAChR levels, and the
role of nicotine in up-regulation of those levels. There is a second way that molecular imaging
techniques can shed light on the neurochemistry of smoking (and drinking). As suggested by
microdialysis studies, the mesolimibic DA system is important as the common pathway
through which all drugs of abuse – and other rewarding inputs - are processed. With PET and
a dopaminergic ligand that competes with DA for binding to a receptor, one could, in theory,
image the effects of reward processing in the brain in response to an addictive substance or
behavior. In practice, such studies have proved quite challenging and the reader must take
care to consider the strengths and weaknesses of each attempt. One challenge is that neither
alcohol nor nicotine causes large elevations of DA levels above baseline – probably only a
doubling or tripling of baseline. And, the effects of both drugs are short-lived. A third challenge
is that self-administration of the substances by a volunteer (smoking a cigarette, drinking a
beer) is not easily performed within the confines of the PET scanner.
4.1. Nicotine and tobacco smoking
Most of the PET studies of the dopaminergic response to cigarette smoking and/or nicotine are
summarized in Table 2. Barrett et al. did one of the earliest studies of smoking with PET; the
first study with smokers actually smoking in the scanner (Barrett et al., 2004). The tracer was
[11C]raclopride, a D2 antagonist that has been found to be sensitive to changes in endogenous
DA (Dewey et al., 1993; Seeman et al., 1989). Barrett et al. used the paired-bolus design
described in Figure 10 (left). But instead of administering the stimulus (i.e., smoking a cigarette)
prior to the tracer, subjects were asked to smoke repeatedly (six times!) while in the scanner
for the one-hour smoking scan. No task was performed during the baseline scan. The authors
did not find any significant change in raclopride binding potential from baseline in any areas
of the striatum when they looked at the results of all 10 smokers together. The study was,
however, characterized by very large variation in ΔBP across smokers (range in ventral
striatum: [-57%, 70%]). When the subjects who experienced “mood elevating effects in response
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to [ ] smoking” (n=5) were broken out from the complete cohort, the authors found a 21%
decrease in BP from baseline (i.e., increase in DA) in the caudate.
There were some notable innovations in the Barrett et al. study as well as some reasons for
caution in interpretation. On the plus side, the smokers smoked in the scanner - thus any DA
release detected could be attributed to the entire smoking behavior – something not possible
with animals but highly relevant for medications development. The smokers were asked to
smoke their own brand - another way of assuring that behavior in the scanner approximated
subjects’ smoking behavior. The authors recognized that, strictly speaking, the comparison of
a baseline BP to one measured under a drug condition requires that a new level of DA be
constant and maintained throughout the latter scan (we will return to this later). Because
smoking probably causes only brief elevation of DA (Di Chiara et al., 1988), the investigators
required repeated cigarettes – starting 15 minutes prior to tracer - in an attempt to achieve a
constant elevated DA during the drug scan. Subjects were also asked to rate the “hedonic
value” of their experience and their craving every 15 minutes during the smoking session. The
investigators probed their data in creative and innovative ways. Across subjects (i.e., one data
point per subject), they looked for correlations at every voxel in the striatum between change
in BP from baseline and craving. R2 values were then converted to t-scores, which were
thresholded at p < 0.05. They found a relationship between craving and ΔBP in dorsal and
posterior areas of striatum.
On the downside, the extreme variability in BP values suggests the possibility of motion artifact
and/or resolution limitations that would preferentially mar the measurement of activity in very
small regions, such as the ventral striatum. Subject motion during smoking is unavoidable and
could easily explain the wild variability between subjects. The protocol of six cigarettes in an
hour is overly demanding and was very likely aversive to some of the subjects. Four subjects
were unable to complete the prescribed regimen of cigarettes. Needless to say, imaging of
aversive stimuli was not the intended aim of the study and would have constituted a confound.
In our own experience, smokers move their heads when they smoke, and they are none too
happy to be asked to smoke a second cigarette even 25 minutes after a first.
Scott et al. took an entirely different approach to both the experimental paradigm and the
analysis (Scott et al., 2007). Their experiment contained only one scan per subject, and yet it
involved a bolus of tracer rather than the more standard single-scan design with a bolus plus
constant infusion. Two denicotinized cigarettes were smoked in succession early in the scan
at 2 and 12 minutes post injection, and two regular nicotine-containing cigarettes were smoked
at minutes 40 and 50 post-tracer injection. By virtue of this design, the investigators are asking
a slightly different question than in other studies, namely, what role does the nicotine in
cigarettes play in DA release? The cohort was extremely small (n=6 right-handed male
smokers). There was also a nonsmoker group scanned at baseline and compared to smokers
under denicotinized cigarettes. The value of this comparison is questionable at best. For
smokers, there was no statistically significant decrease in raclopride binding from denicoti‐
nized to nicotine-containing cigarettes in any subregion of the striatum across the six smokers.
In many of the regions, the reported standard deviations of the BP estimates were quite high,
and the authors would have been well served simply to scan more subjects. As in the case of
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Barrett et al., the investigators looked for and found a correlation between change in BP and
a behavioral (or demographic) measure (Barrett et al., 2004). In the case of Scott, the significant
relationship discovered was between greater decrease in BP (so presumed greater increase in
DA) from denicotinized to nicotine-containing vs. degree of dependence on nicotine (as
measured by the Fagerström score) (Scott et al., 2007). In contrast to Barrett, the Scott finding
was in the ventral striatum. To their credit, Scott et al. corrected their statistical tests for
multiple comparisons.
As with the Barrett paper, the Scott paper involved smoking in the scanner, so motion artifacts
must be considered a real possibility. Although the paper mentions motion-correction, the
state of the art in 2007 would have allowed correction of misalignment between reconstructed
frames acquired over minutes. Nothing could have been done about motion of the subject that
happened within the duration of a single time-frame (we note that with the advent of list-mode
data, high frequency motion monitoring, and interative image reconstruction algorithms,
within-frame motion correction is now possible). The investigators were able to carry out a
bolus design rather than a bolus plus constant infusion because of their innovative analysis
technique. They employed the Logan plot, mentioned above, to linearize the time-activity
curves. Their claim was that they could find two separate slopes (two measures of the ratio of
Vt in the striatum to Vt in the reference region) within the plot. The first slope would reflect
binding of tracer in the early phase of the scan (corresponding to the denicotinized cigarettes),
and the second slope would reflect the later phase (nicotine-containing). In our hands, this
technique is extremely sensitive to the choice of data-range for each slope (Sullivan et al.,
2013), and we have not seen any papers in the literature subsequent to Scott either using or
evaluating said technique.
Two other studies should be mentioned. Like Scott et al., they were both focused on measuring
the nicotine (as opposed to cigarette) effect on DA release in humans. Montgomery et al.
administered nicotine to subjects via nasal spray (Montgomery et al., 2007); Takahashi et al.
had subjects chew nicotine gum (Takahashi et al., 2008). Neither group found any significant
change in BP with nicotine in any individual striatal region. Takahashi showed a significant
decline in [11C]raclopride binding with nicotine administration in the striatum overall. The
former seems like the best design; the latter would seem to be susceptible to motion from
chewing - despite express instructions to subjects to chew with their lower jaw only. Following
up on Scott et al. and Barrett et al., both newer studies looked for correlations between ΔBP
and behavior. Montgomery found a correlation between “happiness” and ΔBP in associative
striatum. In apparent agreement with Scott et al., Takahashi found voxels in the “ventral
putamen” that showed a significant correlation between raclopride ΔBP and Fagerström score.
Finally, the most oft-cited smoking studies were performed by Brody et al. This is the same
group at UCLA that did the study of second-hand smoke’s ability to occupy nAChR, described
above. Brody and colleagues employed yet a different experimental paradigm. Smokers were
scanned with an [11C]raclopride bolus plus constant infusion for 90 minutes (Brody et al.,
2004). From 50 to 60 minutes, the subjects went outside for a “smoke break”. All the while,
they were being infused with [11C]raclopride. Ten smokers smoked a cigarette while outside;
ten did not. All returned and were repositioned in the scanner and scanned for a further 30
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minutes. The data were analyzed with an equilibrium analysis (see Figure 10) comparing BP
at baseline (period just preceding smoke break) with BP after smoking (period just following
smoke break). The major finding was a large (but variable) amount of DA release in ventral
caudate, ventral putamen, which was statistically greater in the smokers who smoked than in
those who did not. In a follow up study, the same group used the same protocol two years
later, and while they replicated the direction of the findings, the effect size was quite a bit
smaller (Brody, Mandelkern, Olmstead, et al., 2006). In both studies, they found that the greater
the reduction of craving for a cigarette from pre- to post-break, the greater the reduction in
raclopride binding potential in the ventral caudate-nucleus accumbens region. The 2006 paper
introduces genetic variation and its possible role in smoking. Subjects were typed for mutations
in the genes that encode for dopamine receptors, dopamine transporter or catechol-O-
methyltransferase (an enzyme that breaks down catecholamines) proteins. Their results
suggest that differences in amount of DA released (change in tracer binding) could be related
to mutation status, and this in turn helps to explain some of the inherent variability in the BP
numbers in both studies.
There are some real strengths to the UCLA design. There is also some reason for concern. First,
there is no smoking in the scanner, so there is no reason to worry about smoking-related head
motion. On the other hand, repositioning the smokers without taking a new transmission scan
could lead to reconstruction artifacts in the post-smoke-break images (transmission and
emission data not aligned). In the investigators’ defense, they also scanned a control group of
smokers who take their break but do not smoke. There is no reason to expect that emission-
transmission misalignment would be more likely in the smokers than in the controls, so it is
probably not the driver of their results. The second – and more subtle – reason for caution in
interpreting the Brody et al. data requires that we first compare their findings in 2004 with
those in 2006.
In the equilibrium analysis, investigators must choose a data window at the end of the pre-
break data to use for a baseline measurement. In both cases, the last 10 minutes of data – from
40-50 minutes – was used. In the 2004 paper, they used 10 minutes of data post-break; in 2006,
they used 30 minutes. The investigators correctly asserted in their second paper that a key
assumption of their analysis is that DA must remain elevated throughout the 30 minutes post-
break (this is why Barrett et al. asked subjects to smoke multiple cigarettes) (Brody, Mandel‐
kern, Olmstead, et al., 2006). Unfortunately, this assumption must be incorrect. If it were true,
then both studies should have found exactly the same change in BP. But in 2006, they found
less of an effect: only 8.4% change as compared to ~30% change in 2004. The explanations
offered by the authors were not persuasive: motion-induced DA release in controls, reposi‐
tioning error. None of these were any more likely to have occurred in the smoking group as
opposed to the control. Rather, the discrepancy between 2006 and 2004 is entirely consistent
with a change in the analysis procedure that, in essence, washed out the effect by averaging
over a period that contains smoking induced DA release and a subsequent period in which
DA levels are returning (have returned) to baseline. In other words, they used too wide a data
window in their second paper. To be sure, we recently did a simulation study of smoking-
induced DA release as measured by raclopride-PET and its dependence on the selection of the
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data window (Sullivan et al., 2013). While the simulations confirmed what we suspected, they
raise an even more troubling concern about all previous attempts to image smoking effects on
DA. That is, how can we compare across studies if people use even slightly different analysis
techniques? How can we compare across groups if the time-period of response of dopamine
to any drug stimulus is short and different between groups? And more generally, how can we
apply standard models that assume “that DA concentration will remain elevated” to PET data
when the assumption is not true? We address this important technical question in the final
section of the chapter following our discussion of drinking studies.
4.2. Imaging dopamine release in response to alcohol
If smoking is difficult for subjects lying in the scanner, it is nevertheless possible. Drinking
while lying in the scanner is not. Researchers have taken two approaches to this problem. The
most obvious study design for measuring alcohol-induced DA release is for the subject to drink
an alcoholic beverage shortly before being scanned and compare raclopride BP in this
condition to either baseline or placebo. This is the approach that was employed by the three
studies to look at drinking-induced DA release, per se. Salonen et al., Boileau et al., and Urban
et al. each used two-scan designs (Boileau et al., 2003; Salonen, 1997; Urban et al., 2010). In each
case, the conditions were either juice or alcohol plus juice. The conditions were randomized
in the latter two studies. The Boileau and Salonen studies each consisted of 6 subjects; Urban
scanned 11 men and 10 women. The subjects were social drinkers. The dose of alcohol was
approximately 1 ml/kg in Boileau and Urban but about 1.3 ml/kg in Salonen. The blood alcohol
levels in each study were consistent and generally reflected the respective doses (measure‐
ments were not taken at the same times, so direct comparisons are difficult). In any case, Urban
claims that the dose in her study was equivalent to 3 standard drinks. Where the paradigms
begin to diverge is the relative timing of alcohol and tracer. The alcohol was taken either 60
minutes, 30 minutes or 5 minutes prior to tracer injection in Salonen, Boileau and Urban,
respectively. A second difference was that in the Urban study, the rim of the juice glass for the
juice-only condition was coated with alcohol to minimize any difference in the subjects’
expectation between conditions. A final noteworthy difference is that the Urban study used
paired bolus plus infusion scans, whereas the other studies both used the more standard
paired-bolus design.
The Salonen and Urban studies were essentially negative. No statistically significant decrease
in [11C]raclopride binding was found in any region of the striatum in the alcohol condition
compared to juice. Boileau reported decreases of 14-15% in raclopride BP in regions that they
termed Nucleus Accumbens and Ventral Putamen. Despite finding no statistically significant
drop in BP in any individual region, Urban reported a sex difference in decrease in BP in all
regions taken together (see paper for further explanation). What is clear from these studies is
that imaging effects of oral alcohol on DA in the striatum is not easy and that we may be at the
limits of detectability for raclopride-PET. Perhaps if we scrutinize elements of each design, we
may find something worth tweaking. In all studies, the amount of alcohol was quite large.
Some subjects – even social drinkers – may have found it aversive. Each study reported at least
one subject who dropped out. As with the smoking studies, the idea is to image drug-taking,
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not aversion. In the Salonen study, the alcohol was taken a lengthy time before the tracer (from
75 – 55 min before). Although the authors were careful to document considerably elevated
blood alcohol at both the beginning and end of the (1 hour) scanning period, one should not
confuse elevated alcohol level with elevated DA. In fact, it is likely that DA responds early to
drinking – possibly to the cues or the rapid rise in brain alcohol and then returns to baseline
more quickly than alcohol level itself. In fact, it appears that Oberlin et al. have demonstrated
that DA responds to the cues for alcohol rather than the alcohol itself (Oberlin et al., 2013).
Consider nicotine. Nicotine remains in the brain for days, but the discrepancy (discussed
above) between the 2004 and 2006 Brody papers (and microdialysis data) certainly suggests
that nicotine-induced DA elevation is rather brief (Brody, Mandelkern, Olmstead, et al., 2006;
Brody et al., 2004). All three alcohol-drinking designs suffer from lack of a baseline condition.
Juice alone is used as a placebo, but if the taste of juice is rewarding then perhaps DA was
released in this condition. There is always a difficulty interpreting any study that contains only
placebo and drug. The difference could be due to changes during drug or changes during
placebo. Consider the Urban design (Urban et al., 2010). In order to control expectation across
conditions, the juice-only glass was rimmed with alcohol. But what if the smell of alcohol
actually set up an expectation of alcohol? In that case, the juice condition was scanned while
the subject experienced disappointment over not receiving the reward. This is called “reward
prediction error” and in monkeys, it has been shown to be the cause of decreased dopaminergic
firing rates as discussed previously (Schultz et al., 1997). Is there any evidence that reward
prediction error leads to alteration of dopamine levels in humans? We must consider one last
raclopride-PET paper to answer that question.
Yoder et al. took a different experimental approach to the study of alcohol-induced DA release
(Yoder et al., 2009). Wary of the variability in alcohol absorption among people, they chose to
administer the alcohol intravenously. The technique, called the “alcohol clamp”, was devel‐
oped by O’Connor et al. and is based on pharmacokinetic modeling of a variable-rate infusion
of alcohol to maintain a constant blood alcohol level in each subject based on their height,
weight, and gender (O'Connor et al., 1998). Second, expectation was controlled through visual
and olfactory cues, which preceded – and predicted - the delivery of alcohol or saline, IV. There
were three conditions scanned in three separate sessions – each scanned with a bolus of
[11C]raclopride. The conditions were as follows: #1: neutral cues signaling IV saline, #2: alcohol
cues signifying alcohol, and #3: neutral cues coupled with unexpected alcohol. This design was
constructed to decouple expectation from consumption of alcohol. The alcohol in condition #2
was delivered after the data acquisition was complete, so the condition can be thought of
“expectation of alcohol but no alcohol consumption” whereas condition #3 – thanks to a little
trickery – can be thought of as “alcohol consumption with no expectation of alcohol”. Subjects’
answers to questionnaires during the scan confirmed that expectations were controlled as
intended. The results were quite provocative: in left ventral striatum, BP of “alcohol con‐
sumption without expectation” went down relative to condition #1. That is, this comparison
signifies increase in DA. But, in the contralateral ventral striatum, BP of “expectation of alcohol
without alcohol consumption” was higher than condition #1. The authors explained this
combination of results as follows. Expectation of reward without reward is equivalent to
negative reward prediction error. Reward without expectation of reward is positive prediction
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error. The caveat in this interpretation is that the subjects (heavy drinkers) must be considered
to have been “conditioned” by their drinking history to respond with appropriate expectation
to the cues. Accepting the author’s interpretation, this paper highlights the importance of
controlling expectation in the study of drugs of abuse. To return to the Urban design (Urban
et al., 2010), if the initial smell of alcohol on the rim of the juice-only glass was a cue for
imminent alcohol reward, then we might expect DA to decrease during this scan. When
compared to a second condition (i.e., alcohol drink), any apparent increase in DA with alcohol
could, in fact, be the result of decrease in the juice-only condition.
Finally, in this section we should point out that there are many other important lines of
investigation of alcohol abuse using PET other than examining DA release. Some have looked
at receptor number (Martinez et al., 2005; Volkow et al., 1996), and others have looked at change
in BP due to drugs for treatment of alcohol. We highlight two studies, briefly. Both studies are
by Weerts et al. (Weerts et al., 2008; Weerts et al., 2011). Both studies looked at the Mu opioid
receptor (MOR) and the Delta opioid receptor (DOR) thanks to the use of two selective tracers,
[11C]carfentail and [11C]methyl-naltrindol. Collectively, the two studies looked at baseline
level of MOR and DOR, as well as occupancy of the receptors due to four days of treatment
with naltrexone, a non-selective opioid receptor antagonist that is prescribed for alcohol abuse.
Baseline receptors in alcoholics were compared to healthy controls, and occupancy of naltrex‐
one was measured in alcoholics only. The main findings were that clinical doses of naltrexone
occupied 95% of MOR but only 75% of DOR. Second, MOR and DOR levels in high binding
regions of the brain were higher in alcoholics than in controls (MOR was significant; DOR was
not). The first finding suggests that any variability on efficacy of naltrexone is probably not
mediated by binding to MOR, since all alcoholics were uniformly blocked. The second finding
suggests that years of drinking may lead to upregulation of MOR and DOR, which is more
like nAChR (Cosgrove et al., 2009) and less like D2 (Martinez et al., 2005).
5. Limitations of conventional modeling methods — Need for new ones
As previously stated, the “conventional” kinetic models used in all of the work discussed to
this point treat BP as a surrogate for number of receptors (because BP = Bmax/KD where Bmax is
available, unoccupied receptors and KD is the affinity of the tracer for the receptor.) Depending
on the circumstance, investigators treat ∆BP as change in available receptors due to altered
number of receptors or altered level of endogenous transmitter occupying sites. Whether the
analysis method is a full fitting of dynamic data or fitting of linearized data via the Logan plot
or measurement of equilibrium levels, the underlying kinetic model is the same. In all cases,
however, a fundamental assumption of the model(s) is that BP is not changing over the course
of the study, because BP is a constant. Mathematically, we say that the kinetic model is time-
invariant in parameters. The inadequacies of all three common methods of analysis in the face
of transient DA release have been thoroughly studied in the recent paper by Sullivan et al
(Sullivan et al., 2013). The reader is directed to that paper for more details. Any violation of
the time-invariant parameters assumption could lead to misinterpretation of data. Many if not
all of the investigators whose work is profiled herein appreciate this limitation of the kinetic
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models. As such, they asked subjects to smoke cigarettes every 15 minutes repeatedly (Barrett
et al., 2004), or they were careful to assay blood alcohol level at start and end of scan and show
that it was the same (Salonen, 1997). Nevertheless, no one can assure that DA remains constant
throughout the PET scan. In fact, in the case of drinking or smoking, it almost certainly does
not. Recall that if smoking-induced DA levels were constant in the Brody experiments, there
would have been no discrepancy between the analyses of the 2004 and 2006 data sets (Brody,
Mandelkern, Olmstead, et al., 2006; Brody et al., 2004). If alcohol drinking-induced DA levels
were constant, there would be no discrepancy between the Boileau finding of change in BP
and the Salonen negative result even though one gave alcohol 30 minutes before the scan, and
the other gave it an hour before (Boileau et al., 2003; Salonen, 1997). What’s more, if the timing
of DA release is different across groups then – as Yoder et al. showed – the mere difference in
timing could result in differences in BP and thus be interpreted as differences in magnitude of
DA release (Yoder et al., 2004).
We have been working over the last ten years to develop kinetic models of tracer uptake and
binding in the presence of transient neurotransmitter release (Constantinescu et al., 2007;
Constantinescu et al., 2008; E. Morris et al., 1995; E. D. Morris et al., 2010; E. D. Morris et al.,
2013; E. D. Morris et al., 2005; M. D. Normandin et al., 2008; M. D. Normandin et al., 2012;
Sullivan et al., 2013). The earlier versions of the model were based on the idea that dopamine
(or any other transmitter that competes with tracer) can exist in the free or bound states in
addition to the various states of the tracer (refer back to Figures 4 and 11). New species in the
model required new “boxes” which, in turn, meant more differential equations (E. Morris et
al., 1995; E. D. Morris et al., 2005). The model described the data well (E. Morris et al., 1995; E.
D. Morris et al., 2008) but was cumbersome to use. Subsequent work by Constantinescu and
by Normandin et al. developed linearized versions of the model that could be solved quickly
(and hence at each voxel) while retaining time-varying terms to describe brief changes in
neurotransmitter level (M. Normandin et al., 2009). Validation of these models was carried out
either (a) by configuring experiments in which a predictable pattern of DA change could be
provoked in human subjects (Constantinescu et al., 2008; E. D. Morris et al., 2010), or (b) a
comparison could be made between model predictions and microdialysis measurements made
in the (rat) subjects at the same time as PET (E. D. Morris et al., 2008; M. D. Normandin et al.,
2008; M. D. Normandin et al., 2012). Most recently, we have adapted the Normandin approach
to the voxel level so that we can estimate time-courses of dopamine at each voxel in the striatum
where “activation” is occurring due to drug stimulus. A critical step in such a process is some
sort of statistical test to determine that change in DA really occurred at that location (voxel) in
question. Finally, the outcome is a collection of curves in time at many voxels in the brain. The
visualization technique that we have invented to display such 4-dimensional results is a
“dopamine movie”, wherein dopamine level is color-coded and the color in the activated
voxels is displayed overlaid on MRI as a series of frames. The methods are described and
demonstrated in a new publication in the Journal of Visualized Experiments (E. D. Morris et
al., 2013). Validation and testing of these new dopamine movies is ongoing. We hope that they
are a more sensitive probe of DA changes in the brain as a consequence of smoking and
drinking behavior and that the increased sensitivity of the method will allow us to tease out
patterns of response that are either “addictive” or “non-addictive”.
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